gemfibrozil has been researched along with diflunisal in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Anan, I; Begum, A; Brännström, K; Gharibyan, AL; Iakovleva, I; Nilsson, L; Olofsson, A; Sauer-Eriksson, AE; Walfridsson, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Kashihara, M; Mizuguchi, M; Yokoyama, T | 1 |
1 review(s) available for gemfibrozil and diflunisal
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for gemfibrozil and diflunisal
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.
Topics: Amyloidosis; Calorimetry; Drug Design; Humans; Ligands; Models, Molecular; Plasma; Prealbumin; Protein Binding; Thermodynamics; X-Ray Diffraction | 2015 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning; Humans; Prealbumin; Thermodynamics; Triclabendazole | 2021 |